BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small molecule design specialist Silicogenix (SGX) to accelerate polypharmacology and non-traditional drug development. The collaboration will combine BioDuro’s drug discovery capabilities with SGX’s design frameworks to streamline the development of complex therapeutics. Headquartered in California, US, BioDuro provides services spanning early […]
The post BioDuro and Silicogenix collaborate to advance non-traditional drug development appeared first on Pharmafile.
